Canopy Growth Corp. (CGC)

40.57
NYSE : Process Industries
Prev Close 40.16
Day Low/High 38.44 / 40.66
52 Wk Low/High 24.21 / 59.25
Avg Volume 4.92M
Exchange NYSE
Shares Outstanding 343.58M
Market Cap 13.93B
EPS -0.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Canopy Growth

Yesterday I reestablished a long position in Canopy Growth  - which has been on my Best Ideas List since early January, 2019.  The shares are responding well to this news.

Short Interest Monitor on Tilray

With Tilray, You Won't Win Any Valuation Arguments

With Tilray, You Won't Win Any Valuation Arguments

Short interest is back in the low single digits while Tilray still enjoys one of the smallest floats for a cannabis company.

Further Bidding

Bidding further to the following longs (but slightly below the market): , and .

Tilray Is Not My Favorite Canadian Cannabis Stock

Tilray Is Not My Favorite Canadian Cannabis Stock

Apparently, this game is all about growth right now. It certainly is not about margins.

Kass: Tilray Is Promising but I Prefer This Other Stock in the Pot Space

Kass: Tilray Is Promising but I Prefer This Other Stock in the Pot Space

Tilray will not be cash flow positive for another 2-3 years - that's not quick enough progress for me given its $7 billion dollar capitalization.

New CGC Move

I am back long Canopy Growth  (very) small (I bought the opening). Moved up my buy entry price in light of a market that seems to be more accepting of speculative stocks.

Stock of the Day - Tilray

Pot stocks like Tilray have very ambitious valuations but the potential upside (in mergers and, fundamentally in food, drink, supplemental and medical applications) are undeniably immense. The view of a possible rapid rise in revenues and profits (a...

Tilray Stock Lights Up as Partnerships Obscure Profitability Problem

Tilray Stock Lights Up as Partnerships Obscure Profitability Problem

The move was helped by the TLRY's deals with AB InBev for beverages and Novartis for medical applications.

Chart of the Day: Vetting the Value of Cannabis Companies

Chart of the Day: Vetting the Value of Cannabis Companies

Assessing Aurora and its peers, strictly on the numbers.

Jim Cramer: AAPL Should Get Into Diabetes Treatment and KHC Should Invest in Pot

Jim Cramer: AAPL Should Get Into Diabetes Treatment and KHC Should Invest in Pot

In this day and age, companies must be 'disruptors' or get left in the dust.

Peltz Is the Perfect Problem Solver for Aurora Cannabis

Peltz Is the Perfect Problem Solver for Aurora Cannabis

Peltz's addition should pacify a persistent critique of the company.

Just How Hot Is Cannabis?

Aurora Cannabis' Is a Beast but the Stock Has Entered a Tricky Area Now

Aurora Cannabis' Is a Beast but the Stock Has Entered a Tricky Area Now

Aurora Cannabis' hiring of deal maker Nelson Peltz opens up a wealth of new possibilities for the Canadian pot company.

Buy Levels

Here are some of my individual buy levels of stocks that I want to add to or reestablish on weakness: * $157.50 * $1625 * $1150 * $42 * $55 * $46 * $46.50 * $182.50 * $31 * $40 * $23 * $65 * $16.75 * $35 * $27.75 * $60 * $95 * $48 * $87.50 Note: Lon...

Jim Cramer: Buy Aurora Cannabis Because Nelson Peltz Knows What Can Go Right

Jim Cramer: Buy Aurora Cannabis Because Nelson Peltz Knows What Can Go Right

I know that Nelson is fascinated by the medicinal properties chiefly as a replacement for opioids, the scourge of this country.

Nelson Peltz Could Be Key to Cannabis in Consumer Packaged Goods

Nelson Peltz Could Be Key to Cannabis in Consumer Packaged Goods

Aurora's prominent partner could be cannabis' key to breaking into consumer segments.

Aurora Cannabis Builds Momentum, Enter Nelson Peltz

Aurora Cannabis Builds Momentum, Enter Nelson Peltz

The plan is for Peltz to help the firm in maximizing potential markets to target.

Melius Research Launches Cannabis Industry Coverage

Melius Research Launches Cannabis Industry Coverage

In its first report on cannabis companies, Melius says prices are high.

Jim Cramer: My Best Stock Picks for Cannabis and China

Jim Cramer: My Best Stock Picks for Cannabis and China

And why I won't recommend any other stocks in these markets, right now.

Revisiting Pot Stocks

A week ago, in 'Up In Smoke' on Feb. 19th, I soured on the short term price outlook for the pot stocks:  Barron's cover story, "You've Got To Be High to Buy U.S. Marijuana Stocks," provides a cautionary outlook for pot stocks. I believe the space is...

A Creative Way to Play Cannabis Stock Canopy Growth

A Creative Way to Play Cannabis Stock Canopy Growth

If you are looking to invest in the fast-growing pot sector, this Canadian cannabis startup has been in early on the action.

Up In Smoke?

Barron's cover story, "You've Got To Be High to Buy U.S. Marijuana Stocks," provides a cautionary outlook for pot stocks. I believe the space is extended and looks like it might be "rolling over" (awful pun!) technically. Canopy Growth is on my Best...

Now Isn't the Time to Gauge Marijuana Stocks

Now Isn't the Time to Gauge Marijuana Stocks

Right now they are speculative growth stocks through and through.

In Simpatico With the Very Reverend James

Rev Shark and I are in simpatico on: * The Bull Market In Complacency (which I discuss in my opener today) * A Possible Change in Market Complexion The former I am relatively certain of. The later will be contingent on a turn down in the absolute pe...

Cannabis Stocks Are Getting Their Second Wind

Cannabis Stocks Are Getting Their Second Wind

Let's check out the charts of four big names in the space.

SLANG Is the Cannabis IPO to Watch This Week

SLANG Is the Cannabis IPO to Watch This Week

While consolidation may be key to the cannabis market in 2019, this IPO is worthy of a deeper dive.

Excuse Me, Would You Like Some Cannabis With Your Coffee?

Excuse Me, Would You Like Some Cannabis With Your Coffee?

CBD could make coffee an around the clock craze.

4 Stocks on the Move

Good action in and two stocks recently added to recently and initiated yesterday ( and ). , a victim of premature selling, is a total monster (+$3). (Still on my Best Idea List).

My Trading Moves

I am pleased with most of my moves over the last six weeks. Some of the better ones were the liquidation of Square and the sale of Amazon and Alphabet  , practically at their highs. While I don't plan to buy back Square at lower prices, I most assur...